Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: A literature-based meta-analysis

Clinical Breast Cancer

Volumn 11, Issue 4, 2011, Pages 246-251

  Xu, Hong Bin ^a   Liu, Yu Jin ^a   Li, Ling ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Advanced breast cancer; Aromatase inhibitor; Hormonal therapy; Meta analysis; Postmenopausal women; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ARTICLE; BONE PAIN; BREAST CANCER; CANCER HORMONE THERAPY; DRUG INDICATION; DRUG SAFETY; HOT FLUSH; HUMAN; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VAGINA BLEEDING;

EID: 80052741670     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.06.003     Document Type: Article

References (23)

1. R. Yancik, and L.A. Ries Aging and cancer in America: demographic and epidemiologic perspectives Hematol Oncol Clin North Am 14 2000 17 23 (Pubitemid 30078429)
2. A.A. Alghanem, and S. Hussain The effect of age on estrogen and progesterone receptor in primary breast cancer J Surg Oncol 30 1985 29 32 (Pubitemid 16249418)
3. J.M. Elwood, and W. Godolphin Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients Br J Cancer 42 1980 635 644 (Pubitemid 11196074)
4. I.A. Jaiyesimi, A.U. Buzdar, and D.A. Decker Use of tamoxifen for breast cancer: twenty-eight years later J Clin Oncol 13 1995 513 529
5. J. Ragaz Status of aromatase inhibitors in relation to other breast cancer treatment modalities Endocr Relat Cancer 6 1999 277 291 (Pubitemid 29260064)
6. P.E. Goss, J.N. Ingle, and S. Martino A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 2003 1793 1802 (Pubitemid 37362955)
7. B. Gerber, A. Krause, and T. Reimer Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine- responsive breast cancer and tamoxifen-induced endometrial pathology Clin Cancer Res 12 2006 1245 1250 (Pubitemid 43342515)
8. E.A. Perez Safety of aromatase inhibitors in the adjuvant setting Breast Cancer Res Treat 105 suppl 1 2007 75 89 (Pubitemid 47524804)
9. R.J. Paridaens, L.Y. Dirix, and V. Louk Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group J Clin Oncol 26 2008 4883 4890
10. H. Mouridsen, and H.A. Chaudri-Ross Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer Oncologist 9 2004 497 506 (Pubitemid 39332313)
11. R.J. Paridaens, L.Y. Dirix, and C. Lohrisch Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer Ann Oncol 14 2003 1391 1398 (Pubitemid 37185285)
12. A. Milla-Santos, L. Milla, and J. Portella Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study Am J Clin Oncol 26 2003 317 322 (Pubitemid 36712651)
13. J. Bonneterre, B. Thurlimann, and J.F. Robertson Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study J Clin Oncol 18 2000 3748 3757
14. J.M. Nabholtz, A. Buzdar, and M. Pollak Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial Arimidex Study Group J Clin Oncol 18 2000 3758 3767
15. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188 (Pubitemid 17189972)
16. J.P. Higgins, S.G. Thompson, and J.J. Deeks Measuring inconsistency in meta-analyses BMJ 327 2003 557 560 (Pubitemid 37088507)
17. G.G. Kimmick, and L. Balducci Breast cancer and aging: clinical interactions Hematol Oncol Clin North Am 14 2000 213 234 (Pubitemid 30078439)
18. C. Rose, and H.T. Mouridsen Endocrine therapy of advanced breast cancer Acta Oncol 27 1988 721 728 (Pubitemid 19051897)
19. J.M. Dixon Exemestane and aromatase inhibitors in the management of advanced breast cancer Expert Opin Pharmacother 5 2004 307 316 (Pubitemid 38219857)
20. R. Paridaens, J. Thomas, and J. Wildiers Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: A phase I study Anticancer Drugs 9 1998 675 683 (Pubitemid 28495452)
21. S. Jones, C. Vogel, and A. Arkhipov Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer: Aromasin Study Group J Clin Oncol 17 1999 3418 3425 (Pubitemid 29517909)
22. A. Hamilton, and M. Piccart The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer Ann Oncol 10 1999 377 384 (Pubitemid 29236413)
23. P. Predbois, and M. Buyse Meta-analysis based on abstracted data: a step in the right direction, but only a first step J Clin Oncol 22 2004 3839 3841 (Pubitemid 41079861)